Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE HIVES versus PROMETH PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE HIVES versus PROMETH PLAIN.
FEXOFENADINE HYDROCHLORIDE HIVES vs PROMETH PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine hydrochloride is a selective peripheral H1-receptor antagonist. It blocks the action of histamine at the H1 receptor, preventing histamine-mediated symptoms such as itching, sneezing, rhinorrhea, and urticaria.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
60 mg orally twice daily or 180 mg orally once daily
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life is 14.4 hours (range 11–17 hours) in healthy adults. Clinically, this supports twice-daily dosing for symptomatic relief.
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Approximately 95% of the dose is excreted unchanged in feces (80%) and urine (15%). Fexofenadine undergoes minimal hepatic metabolism (<5%).
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Category A/B
Category C
Antihistamine
Antihistamine